0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > RAGE

RAGE

RAGE Molecule Information

Name:Advanced glycosylation end product-specific receptor
Target Synonym:Receptor for advanced glycosylation end products,AGER,Advanced Glycosylation End-Product Specific Receptor,RAGE,Receptor For Advanced Glycation End-Products Variant 20,Receptor For Advanced Glycation End-Products,RAGE Isoform NtRAGE-Delta,RAGE Isoform SRA
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

RAGE Molecule Synonym Name

AGER,RAGE

RAGE Molecule Background

Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

RAGE References

RAGE Related Molecule

RAGE Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TRC-4186 TX-41XX; TRC-4186 Phase 2 Clinical Torrent Pharmaceuticals Heart Failure; Diabetes Complications Details
TRC-041266 TRC-041266 Phase 3 Clinical Torrent Pharmaceuticals Heart Failure Details

This web search service is supported by Google Inc.

totop